As Chief Administrative Law Judge Derek Julius weighs his recommendation on moving cannabis to Schedule III, the DEA’s own closing
The Drug Enforcement Administration’s (DEA) administrative hearing on cannabis rescheduling saw both sides make their closing arguments on Wednesday, July
Tomorrow (July 15, 2026) the landmark administrative hearing on US cannabis rescheduling will come to a close. Today (July 14),
On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA
Trulieve’s uplisting to the NYSE, the first of its kind in US history, has undoubtedly caught the attention of every
Cannabis stocks have, for the last five years or so, represented one of, if not the worst-performing, niche categories on
The critical June 29 administrative hearing, set to determine whether the US will extend rescheduling efforts to recreational cannabis, is
For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug
Cannabis Europa London returns on 26-27 May 2026, bringing together operators, investors, clinicians and policymakers from across the global cannabis
Since President Trump issued an executive order to expedite cannabis rescheduling in December 2025, questions over the legal implications of this
Reclassification confusion, an IPO revival in cannabis pharma and a contentious DEA registration form dominate today’s cannabis news, alongside fresh European consolidation and a return of investor focus on the sector’s ETFs.
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling
Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators. With
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling
The White House’s commitment to push through rescheduling has been challenged by a Democratic Senator, who has demanded answers on
The Trump administration’s continued inaction on its promise to push ahead with the highly anticipated cannabis rescheduling project is now
We won’t spam you
